āagman

Not investment advice. Data and computed figures, for information only.

Piramal Pharma Ltd

NSE: PPLPHARMA
₹194.43
+₹0.49 (+0.25%)
NSE · 15 Oct 2026, close
NSE
As of 31 Mar 2026
Market Cap
₹26,212 Cr
CMP
₹194.43
52-wk High / Low
₹232 / 132
P/B
3.2
Book Value
₹61.4
Div Yield
0.00%
ROCE
3.0%
ROE
−3.8%
Face Value
₹10
D/E
0.70

Price−3.6% over 1Y

āagman read

Computed by āagman
Derived from 6 years and 13 quarters of filings. Not reported by the company.
As of 15 Oct 2026
How we compute these
Piotroski F-Score
2
/ 9
2 of 9 F-score tests passed
ROIC
0.7%
vs 11.2% sector median
Cash flow to profit
−5.07
CFO / PAT
Above 1.0 = operating cash flow exceeded reported profit
Margin change
+306
bps OPM YoY
Operating margin vs the same quarter last year
ROE stability
3.4
pp σ
Standard deviation of ROE across periods. Lower = more stable
Holder deltas
QoQ
pp
Prom −0.05FII −17.66DII −1.04
Latest quarter vs the previous one
Cash-accrual divergence
−12.0%
of assets
Low = accruals track cash flow
Strengths
+Price trades above its 200-day moving average (1.1x)
Watch-outs
−Latest ROCE of 3% trails the sector median of 17%
−Piotroski F-Score of 2/9 is in the weak band (≤3)

Peer comparison

Peers
NameP/EMar Cap ₹ CrROCE %ROE %

Quarterly results

Consolidated basis (as filed) · ₹ Cr · 13 quarters
As of 30 Jun 2026
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales1,7491,9111,9592,5521,9512,2422,2042,7541,9342,0442,1402,7522,270
Expenses1,6171,6461,6902,0221,7471,9001,8662,1931,8271,8851,9442,2912,075
Operating Profit132266268530204342338561107159196461195
OPM %7.5%13.9%13.7%20.8%10.5%15.3%15.3%20.4%5.5%7.8%9.2%16.8%8.6%
Other Income536843842782958988012−116109
Interest1191101061141071081031048682898388
Depreciation174185186196185192197243197203213218224
Profit before tax−1074019227−4512067273−79−46−9443−7
Net Profit−99510101−89234154−82−99−136−9−69
EPS (₹)−0.750.040.080.77−0.670.170.031.16−0.61−0.75−1.02−0.07−0.52

Profit & Loss

As of 30 Jun 2026
Consolidated · ₹ Cr · 6 years + TTM
Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales6,3156,5597,0828,1719,1518,8699,205
Expenses4,8875,6096,4536,9747,7067,9478,195
Operating Profit1,4289506291,1971,4459221,010
OPM %22.6%14.5%8.9%14.6%15.8%10.4%11.0%
Other Income2303192721722087486
Interest163198344448422341343
Depreciation545586677741816831858
Profit before tax949485−120179415−176−104
Net Profit835376−1861891−326−314
EPS (₹)——−1.410.130.69−2.45−2.36

Balance Sheet

As of 30 Jun 2026
Consolidated · ₹ Cr
Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Jun 2026
Equity Capital9951,1861,1931,3231,3241,327—
Reserves4,6105,5115,5806,5886,8016,835—
Borrowings3,0254,1285,6374,7104,8565,675—
Other Liabilities2,0471,7811,8932,4612,4473,770—
Total Liabilities10,67712,60514,30315,08315,42917,607—
Fixed Assets6,1056,8797,4697,9908,1338,684—
CWIP6271,1721,4191,1169771,100—
Investments123267639385291437—
Other Assets3,8224,2864,7775,5926,0287,386—
Total Assets10,67712,60514,30315,08315,42917,607—

Cash Flows

As of 31 Mar 2026
Consolidated · ₹ Cr
Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity5987664841,0058921,653
Cash from Investing Activity−4,464−1,737−1,334−416−488−820
Cash from Financing Activity3,977794818−422−441−39
Net Cash Flow110−177−32166−37794

Ratios

As of 31 Mar 2026
6 periods
Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %—7.02.05.06.03.0
ROE %—————−3.8
EPS (₹)——−1.410.130.69−2.45
Book Value (₹)—————61.4
Face Value (₹)—————10
P/E——————
Div Yield %—————0.00
NPM %12.85.5−2.50.21.0−3.6
OPM %23.014.09.015.016.010.0
D/E0.540.620.830.600.600.70
P/B—————3.2

Growth

As of 11 Oct 2026
Compounded sales growth
5 years+7.0%
3 years+8.0%
TTM+1.0%
Compounded profit growth
3 years−31.0%
TTM−296.0%
Stock price CAGR
3 years+26.0%
Last year−2.0%
Return on equity
5 years0.0%
3 years−1.0%
Last year−4.0%

Shareholding pattern

As of 30 Sep 2024
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
Promoters34.78%34.78%35.02%34.94%34.85%34.80%
FIIs39.28%39.28%30.58%31.49%30.17%12.51%
DIIs4.98%4.98%12.12%14.78%15.61%14.57%
Government——————
Public20.57%20.57%21.89%18.42%19.01%37.62%
No. of shareholders2,41,3592,41,3592,97,9964,32,8434,50,6614,61,096
Change since Jun 2023 (pp)
Promoters +0.02FIIs −26.77DIIs +9.59Public +17.05

Documents

As of 11 Oct 2026
Announcements
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 - Expiry And Non-Renewal Of Commercial Arrangement With Bayer Pharmaceuticals Private LimitedClarification On News Item Which Appeared In The 'Www.Thehindubusinessline.Com' Dated September 30, 2026 Captioned 'Ontario Contributes $1.7 Million Investment To Advance Life Sciences Innovation At Piramal Pharma'S Aurora Facility.'Announcement under Regulation 30 (LODR)-Change in ManagementClarification sought from Piramal Pharma LtdAnnouncement under Regulation 30 (LODR)-Change in Management
Annual reports
Annual Report 2026Annual Report 2025Annual Report 2024Annual Report 2023
Credit ratings
Rating updateRating updateRating updateRating updateRating update
Concalls
Jul 2026TranscriptJul 2026PPTJul 2026RecordingApr 2026TranscriptApr 2026PPTApr 2026RecordingJan 2026TranscriptJan 2026PPTNov 2025TranscriptNov 2025PPTOct 2025Transcript

Corporate actions

As of 16 Jul 2025
16 Jul 2025DIVIDENDDividend - Re 0.14 Per Share—
12 Jul 2024DIVIDENDDividend - Rs 0.11 Per Share—
2 Aug 2023RIGHTSRights 5:46 @ Premium Rs 71/-—
Fundamentals from a third-party compiler of exchange filings; prices from the exchanges. Not investment advice.© 2026 āagman